{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061998","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.353697+00:00","generated_at":"2026-06-01T23:44:03.363971+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life","bullets":["Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).","Phase 1 healthy volunteer data showed half-life of ~75 days and potentially best-in-class PK profile.","16-week proof-of-concept data from Part A expected in 2H 2025; dose optimization Part B also planned.","APG777 designed for less frequent dosing: 6 injections during induction vs 11 for lebrikizumab, 70-90% fewer in maintenance.","Phase 2 asthma trial expected to initiate in 2025; pipeline-in-a-product strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061998","json":"https://secwatch.observer/filing/0001104659-24-061998.json","markdown":"https://secwatch.observer/filing/0001104659-24-061998.md","text":"https://secwatch.observer/filing/0001104659-24-061998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/0001104659-24-061998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/tm2414616d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:44:03.363971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}